Trials / Unknown
UnknownNCT05801094
A Phase I Study of QL1604 for Advanced Solid Tumors
A Phase I Clinical Study to Evaluate Safety、 Tolerability, and Pharmacokinetics of QL1604 for the Treatment of Advanced Solid Tumors - A Phase Ic Preliminary Efficacy Expansion Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1604 | QL1604 3 mg/kg Q3W |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2023-04-15
- Completion
- 2023-12-15
- First posted
- 2023-04-06
- Last updated
- 2023-04-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05801094. Inclusion in this directory is not an endorsement.